Integrase Interactor 1 (INI1) Deficiency in a Lung Cancer Patient Presents Nonresponse to Immunotherapy and Tazemetostat: A Case Report

Integrase interactor 1 (INI1)-deficient lung cancer is extremely rare, often with poor prognosis, and lacks effective treatment. Previous studies have reported the efficacy of immunotherapy and enhancer of the zeste homolog 2 (EZH2) inhibitor tazemetostat in various types of INI1-deficient tumors, s...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiuxiu, Wu, Jiaji, Pang, Guanchao, Wei, Shumei, Wang, Pingli
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Internal Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475322/
https://www.ncbi.nlm.nih.gov/pubmed/37667707
http://dx.doi.org/10.7759/cureus.42934

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475322/
https://www.ncbi.nlm.nih.gov/pubmed/37667707
http://dx.doi.org/10.7759/cureus.42934

Ejemplares similares